Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase III Clinical Study of Omidubicel in Patients with Hematologic Malignancies

Gamida Cell Ltd. announced that the Phase III study of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant, met all three of its secondary endpoints.
[Gamida Cell Ltd.]
Press Release
Bookmark

No account yet? Register

0
Share

The Functional Interplay of Transcription Factors and Cell Adhesion Molecules in Experimental Myelodysplasia including Hematopoietic Stem Progenitor Compartment

Scientists made an attempt to find out the osteoblastic niche related alterations in the myelodysplastic bone marrow through mainly flowcytometric and fluorescent microscopic studies.
[Molecular and Cellular Biology]
Daw, S., & Law, S. (2020). The functional interplay of transcription factors and cell adhesion molecules in experimental myelodysplasia including hematopoietic stem progenitor compartment. Molecular and Cellular Biochemistry. https://doi.org/10.1007/s11010-020-03920-6 Cite
Abstract
Bookmark

No account yet? Register

0
Share

bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. announced that the European Medicines Agency accepted the company’s MAA for its investigational elivaldogene autotemcel gene therapy for the treatment of patients with CALD.
[bluebird bio, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Nanoparticle-Encapsulated siRNAs for Gene Silencing in the Haematopoietic Stem-Cell Niche

Researchers report the design and in vivo performance of systemically injected lipid–polymer nanoparticles encapsulating small interfering RNA, for the silencing of genes in bone-marrow endothelial cells.
[Nature Biomedical Engineering]
Krohn-Grimberghe, M., Mitchell, M. J., Schloss, M. J., Khan, O. F., Courties, G., Guimaraes, P. P. G., Rohde, D., Cremer, S., Kowalski, P. S., Sun, Y., Tan, M., Webster, J., Wang, K., Iwamoto, Y., Schmidt, S. P., Wojtkiewicz, G. R., Nayar, R., Frodermann, V., Hulsmans, M., … Nahrendorf, M. (2020). Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche. Nature Biomedical Engineering, 1–14. https://doi.org/10.1038/s41551-020-00623-7 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Platelet-Derived Microparticles Enhance Megakaryocyte Differentiation and Platelet Generation via miR-1915-3p

The authors showed that, during mouse acute liver injury, the density of megakaryocyte in the bone marrow increases following an increase in circulating platelet-derived microparticles, but without thrombopoietin upregulation.
[Nature Communications]
Qu, M., Zou, X., Fang, F., Wang, S., Xu, L., Zeng, Q., Fan, Z., Chen, L., Yue, W., Xie, X., & Pei, X. (2020). Platelet-derived microparticles enhance megakaryocyte differentiation and platelet generation via miR-1915-3p. Nature Communications, 11(1), 4964. https://doi.org/10.1038/s41467-020-18802-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Competitive sgRNA Screen Identifies p38 MAPK as a Druggable Target to Improve HSPC Engraftment

Scientists performed a targeted CRISPR-Cas9-based sgRNA screen to identify candidate genes that counteract the decreased repopulating capacity of hematopoietic stem and progenitor cells during gene therapy.
[Cells]
Klatt, D., Ha, T.-C., Schinke, M., Selich, A., Lieske, A., Dahlke, J., Morgan, M., Maetzig, T., & Schambach, A. (2020). Competitive sgRNA Screen Identifies p38 MAPK as a Druggable Target to Improve HSPC Engraftment. Cells, 9(10), 2194. https://doi.org/10.3390/cells9102194 Cite
Full Article
Bookmark

No account yet? Register

0
Share

HbF Levels in Sickle Cell Disease Are Associated with Proportion of Circulating Hematopoietic Stem and Progenitor Cells and CC-Chemokines

Researchers report that the proportions of Lin-CD34+38 hematopoietic multipotent cells and of Lin-CD34+CD38+ hematopoietic progenitors cells are highly variable between individuals but stable over long periods of time, in both healthy individuals and sickle cell disease patients.
[Cells]
Minniti, C. P., Tolu, S. S., Wang, K., Yan, Z., Robert, K., Zhang, S., Crouch, A. S., Uehlinger, J., Manwani, D., & Bouhassira, E. E. (2020). HbF Levels in Sickle Cell Disease Are Associated with Proportion of Circulating Hematopoietic Stem and Progenitor Cells and CC-Chemokines. Cells, 9(10), 2199. https://doi.org/10.3390/cells9102199 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Splenic Hematopoietic and Stromal Cells in Cancer Progression

Tumor-derived secretory factors orchestrate splenic hematopoietic and stromal cells to fuel metastasis. The spleen acts as a reservoir site for hematopoietic stem and progenitor cells, which are rapidly exploited as myeloid-derived suppressor cells at the cost of tumor-reactive lymphoid cells.
[Cancer Research]
Steenbrugge, J., Jaeghere, E. A. D., Meyer, E., Denys, H., & Wever, O. D. (2020). Splenic hematopoietic and stromal cells in cancer progression. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-20-2339 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Haploinsufficiency of Cohesin Protease, Separase, Promotes Regeneration of Hematopoietic Stem Cells in Mice

Researchers report that partial disruption of Separase distinctly alters the functional characteristics of hematopoietic stem/progenitor cells.
[Stem Cells]
Kumar, P., Cheng, H., Paudyal, S., Nakamura, L. V., Zhang, N., Li, J. T., Sasidharan, R., Jeong, M., & Pati, D. (n.d.). Haploinsufficiency of Cohesin Protease, Separase, Promotes Regeneration of Hematopoietic Stem Cells in Mice. STEM CELLS, n/a(n/a). https://doi.org/10.1002/stem.3280 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

Avalon GloboCare Corp. provided a clinical update on its chimeric antigen receptor (CAR) T-cell therapy and allogeneic mesenchymal stromal cell (MSC) therapy programs following successful completion of its Phase I clinical trial of AVA-001, the company’s leading CAR T-cell therapy candidate in development for patients with relapsed/refractory B-cell lymphoblastic leukemia.
[Avalon GloboCare Corp. (GlobeNewswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

High-Fat Diet Intensifies MLL-AF9-Induced Acute Myeloid Leukemia through Activation of the FLT3 Signaling in Mouse Primitive Hematopoietic Cells

Using a MLL-AF9 knock-in mouse model, researchers discovered that consumption of a high-fat diet accelerates the risk of developing acute myeloid leukemia.
[Scientific Reports]
Hermetet, F., Mshaik, R., Simonet, J., Callier, P., Delva, L., & Quéré, R. (2020). High-fat diet intensifies MLL-AF9 -induced acute myeloid leukemia through activation of the FLT3 signaling in mouse primitive hematopoietic cells. Scientific Reports, 10(1), 16187. https://doi.org/10.1038/s41598-020-73020-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share